Comparative Pharmacology
Head-to-head clinical analysis: HUMALOG MIX 75 25 versus NOVOLOG FLEXPEN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: HUMALOG MIX 75 25 versus NOVOLOG FLEXPEN.
HUMALOG MIX 75/25 vs NOVOLOG FLEXPEN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Biphasic insulin analog combining rapid-acting insulin lispro (25%) and intermediate-acting insulin lispro protamine suspension (75%). Insulin lispro lowers blood glucose by binding to insulin receptors, facilitating cellular glucose uptake, inhibiting hepatic gluconeogenesis, and promoting glycogenesis and lipogenesis.
Insulin analog that lowers blood glucose by binding to insulin receptors, facilitating cellular uptake of glucose, and inhibiting hepatic glucose production.
Subcutaneous injection: 75% insulin lispro protamine suspension and 25% insulin lispro solution. Dose individualized based on glycemic goals and prior insulin regimen. Typical total daily dose: 0.5-1 unit/kg/day divided into two doses (pre-breakfast and pre-dinner).
Subcutaneous injection; 0.5 to 1.0 unit/kg/day divided into doses at mealtimes; dose individualization based on metabolic needs and blood glucose monitoring.
None Documented
None Documented
Insulin lispro: 0.5-1 hour; protamine-bound fraction prolongs absorption, resulting in a biphasic profile with an effective half-life of 2-4 hours for the 75% NPL component.
Terminal elimination half-life: 5-7 minutes (free insulin aspart in plasma); clinically, the prolonged action (up to 6 hours) reflects continued absorption from subcutaneous depot, not elimination half-life
Renal: 60-80% as unchanged drug following subcutaneous absorption; the remaining fraction undergoes hepatic metabolism and biliary/fecal excretion.
Primarily renal (60-80% as unchanged drug via glomerular filtration and tubular reabsorption); biliary/fecal excretion minimal (<2%)
Category C
Category C
Insulin Analog
Insulin Analog